Earnings Feed
Start Free
Home/Filings/4/0001179110-09-012863
4//SEC Filing

LONBERG NILS 4

Accession 0001179110-09-012863

CIK 0000874255other
View on SEC.govCompany Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:03 PM ET

Size

43.1 KB

Accession

0001179110-09-012863

Insider Transaction Report

Form 4
Period: 2009-09-01
MEDAREX INCMEDX
LONBERG NILS
Sr. VP, Scientific Director
Transactions
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−13,976$223,616→ 0 total
    Exercise: $7.16Exp: 2013-10-13→ Common Stock (13,976 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−25,000$400,000→ 0 total
    Exercise: $6.33Exp: 2013-09-07→ Common Stock (25,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−186,024$2,976,384→ 0 total
    Exercise: $7.16Exp: 2013-10-13→ Common Stock (186,024 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−239,899$3,838,384→ 0 total
    Exercise: $9.90Exp: 2015-09-05→ Common Stock (239,899 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−100,000$1,600,000→ 0 total
    Exercise: $14.89Exp: 2011-09-18→ Common Stock (100,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−167,158$2,674,528→ 0 total
    Exercise: $5.61Exp: 2014-07-25→ Common Stock (167,158 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−169,152$2,706,432→ 0 total
    Exercise: $3.43Exp: 2009-10-31→ Common Stock (169,142 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−43,000$688,000→ 0 total
    → Common Stock (43,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−17,842$285,472→ 0 total
    Exercise: $5.61Exp: 2014-07-25→ Common Stock (17,842 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−54,848$877,568→ 0 total
    Exercise: $3.43Exp: 2010-05-17→ Common Stock (54,848 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−10,101$161,616→ 0 total
    Exercise: $9.90Exp: 2015-09-05→ Common Stock (10,101 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−200,000$3,200,000→ 0 total
    Exercise: $8.11Exp: 2012-07-10→ Common Stock (200,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−129,000$2,064,000→ 0 total
    Exercise: $9.07Exp: 2018-03-02→ Common Stock (129,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−14,119$225,904→ 0 total
    → Common Stock (14,119 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−150,000$2,400,000→ 0 total
    Exercise: $14.92Exp: 2017-05-16→ Common Stock (150,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2009-09-01$16.00/sh−129,000$2,064,000→ 0 total
    Exercise: $3.72Exp: 2019-03-04→ Common Stock (129,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2009-09-01$16.00/sh−43,000$688,000→ 0 total
    → Common Stock (43,000 underlying)
Footnotes (21)
  • [F1]This option was canceled in the merger in exchange for a cash payment of $123,617.72, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F10]This option was canceled in the merger in exchange for a cash payment of $1,737,607.41, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F11]This option was canceled in the merger in exchange for a cash payment of $1,463,383.90, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F12]This option was canceled in the merger in exchange for a cash payment of $162,750.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F13]This option was canceled in the merger in exchange for a cash payment of $894,615.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F14]This option was canceled in the merger in exchange for a cash payment of $1,584,120.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F15]Each Restricted Stock Unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
  • [F16]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $225,904.00, based on the merger consideration ($16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
  • [F17]Receipt of the Restricted Stock Units was deferred until February 23, 2010.
  • [F18]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $516,000.00, based on the merger consideration ($16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
  • [F19]The Restricted Stock Units vested ratably over four years beginning on April 3, 2009.
  • [F2]This option was canceled in the merger in exchange for a cash payment of $185,467.59, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F20]This Restricted Stock Unit was canceled in the merger in exchange for a cash payment of $688,000 based on the merger consideration ($16 per share) pursuant to the merger agreement between issuer and Bristol-Myers Squibb.
  • [F21]The Restricted Stock Units vested ratably over four years beginning on April 5, 2010.
  • [F3]This option was canceled in the merger in exchange for a cash payment of $61,616.10, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F4]This option was canceled in the merger in exchange for a cash payment of $2,126,240.60, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb
  • [F5]This option was canceled in the merger in exchange for a cash payment of $689,439.36, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F6]This option was canceled in the merger in exchange for a cash payment of $111,000, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F7]This option was canceled in the merger in exchange for a cash payment of $1,578,000, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F8]This option was canceled in the merger in exchange for a cash payment of $241,750.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F9]This option was canceled in the merger in exchange for a cash payment of $1,645,382.28, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

Documents

1 file

Issuer

MEDAREX INC

CIK 0000874255

→
Entity typeother

Related Parties

1
  • filerCIK 0001214506

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:03 PM ET
Size
43.1 KB
View on SEC.gov